New Triple-Threat treatment tested for Tough-to-Treat breast cancer
NCT ID NCT07405801
Summary
This study is testing whether adding a new drug called inavolisib to two existing breast cancer drugs works better than the standard two-drug combination. It is for people whose advanced breast cancer has stopped responding to hormone therapy and who have a specific genetic pattern in their tumor. The main goal is to see if the three-drug combo shrinks tumors more effectively and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CIUSSS du Saguenay Lac-Saint-Jean, Chicoutimi Hospital
RECRUITINGChicoutimi, Quebec, G7H 5H6, Canada
-
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
RECRUITINGSão Paulo, São Paulo, 01317-000, Brazil
-
Gachon University Gil Medical Center
RECRUITINGNamdong-Gu, 21565, South Korea
-
McGill University
RECRUITINGMontreal, Quebec, H4A 3J1, Canada
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam-si, 13605, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Soon Chun Hyang University Cheonan Hospital
RECRUITINGDongnam-gu, Cheonan-si, 31151, South Korea
Conditions
Explore the condition pages connected to this study.